In this edition:

• NICE updates: ruxolitinib and glycopyrronium cream

• LDOM in paediatric patients

• A Delphi consensus on chronic prurigo

• A systematic review of dupilumab-associated facial and neck erythema

• Zinc deficiency in bullous pemphigoid

• Determinants of real-world sunscreen effectiveness

• Does gamification improve training?

• Ruxolitinib ‘super responders’ in vitiligo treatment

• Oestrogen therapy for menopausal hair loss?

• European SCC guidelines

• Does Senital Node Biopsy improve survival in melanoma patients?

  
  

• Co-treating Ixekizumab With Tirzepatide - does it enhance response?

  
  

• Adjuvant cemiplimab in high-risk SCC, does it help?

  
  

• Do we need to do CXR before starting methotrexate?

  
  

• How effective are systemics at controlling generalised pustular psoriasis?

  
  

• Stage IIC vs IIIA melanoma survival analysis

• Salt immersion as a treatment for warts

• Targeted reapplication of treatment for scabies in infants

• Changes to Advice and Guidance in NHS England

• Weekly or daily bathing in patients with eczema?

• Which devices to use in patient teledermoscopy?

• Does AI improve FDS in real world application?

• LPP guidance from EADV

• Hep B guidance for patients on systemics

Highlights:

• A new way of thinking about diagnosing mosaic pigmentary disorders

• Nail melanoma and melanonychia - length of monitoring and changes to look out for

• Cutaneous immune-related adverse events and oncological outcomes

• A Delphi consensus on Topical Steroid Withdrawal

• European HS guidelines

• Frontal Fibrosing Alopecia in men : a systematic review

• Validated tools to help with suspected drug allergies and how to approach allergy labelling

• Hydrocolloid dressing vs petroleum ointment application post op - how do they compare?

AGA Guidelines

There is a large void when it comes to guidelines for the treatment of androgenetic alopecia, specifically FPHL. In this final lesson, we bring it all together, with recently published 2025 guidelines that help to fill that void and provide worldwide guidance, reflecting common practice in the UK and elsewhere.

Platelet Rich Plasma (PRP)

Some clinicians swear by it, others have had a less favourable experience with it. So, what’s the low-down on PRP for FPHL?

Low Level Laser Light Therapy (LLLT)

Everyone’s talking about it. But should we be recommending it? And if so, which devices? How often? Let’s review the recent evidence.

Low Dose Oral Minoxidil (LDOM)

There is a lot of hype around LDOM and it is increasingly used for all types of alopecia. But, what doses should we use? Do we need to monitor it? And what are the side effects? We summarise the evidence here.